News

Company has received approval to initiate a phase I human trial to evaluate Inovio’s Zika DNA vaccine to prevent infection from this concerning virus.

Storm Therapeutics has secured £12 million in series ‘A’ funding from Imperial Innovations, Cambridge Innovation Capital, Merck Ventures and Pfizer Venture Investments.

A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).

Partnership aims to combine 3Scan’s 3dimensional reconstructive imaging process while sectioning tissue samples with the integrative genomic and multiscalar data analysis services offering by SII.

Partnership aims to develop a joint platform to research precision medicine.

Agri-Tech East cluster supports pipeline of innovation with the UK's only national agri-tech business plan competition.

Cancer cells appear to depend on an unusual survival mechanism to spread around the body, according to an early study led by Queen Mary University of London.

A CRO to meet market demand for better and accelerated drug discovery and development to improve efficiency in establishing drug candidate success.

Company has announced collaboration with Innovent Biologics for the development of bispecific antibodies.

Company has announced the initiation of a Phase II expansion of the ongoing TATTON trial to evaluate the selective c-Met inhibitor savolitinib in EGFR mutant NSCLC.